Horizon Discovery Ltd. signs second commercial agreement with Genentech Inc.

01 Dec 2007

Horizon Discovery (Horizon) has signed a second commercial agreement to supply leading US biotechnology company Genentech, Inc. with access to its OncoGene panel of isogenic cell-lines.

The financial terms of both deals remain confidential but involve payment of up-front, annual renewal and milestone payments.

Chris Torrance, Horizon CSO says: “We are delighted to have Genentech as an early-adopter of the OncoGene panel. The licensed cell-lines in this panel represent novel drug discovery tools that accurately model specific genetic mutations observed in real human cancer cells”.